Elia Seguí

6PUBLICATIONS

74CO-AUTHORS

Molecular targetsPredictive and prognostic markersSolid tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jul 13, 2026

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

|Jan 22, 2026

Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

|Sep 14, 2024

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.

Elia Seguí, Juan Manuel Torres, Edouard Auclin

|Apr 13, 2024

Characterisation and Outcomes of Patients with Solid Organ Malignancies Admitted to the Intensive Care Unit: Mortality and Impact on Functional Status and Oncological Treatment.

Marta García de Herreros, Juan Carlos Laguna, Joan Padrosa

|Sep 23, 2022

Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature.

Elia Seguí, Carles Zamora-Martínez, Tanny Daniela Barreto

|Sep 09, 2022

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.

Giovanna Garufi, Luisa Carbognin, Francesco Schettini

Pageof 1

Frequent Collaborators

3 joint publications

Aleix Prat

2 joint publications

Carles Zamora-Martínez

Joan Padrosa

Juan Carlos Laguna

Francesco Schettini

Alba Di Leone

Antonio Franco

Ida Paris

Alessandra Fabi

Albert Tuca

Frequent Collaborators

3 joint publications

Aleix Prat

2 joint publications

Carles Zamora-Martínez

2 joint publications

Joan Padrosa

2 joint publications

Juan Carlos Laguna